You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
GANGLIOSIDE ANTIBODY PANEL 6 |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB1308 Geisinger Epic ID: 53157 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
|
|
Specimen required: |
2 mL serum; minimum 1 mL. | |
Patient preparation: |
Overnight fasting is preferred. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Centrifuge and aliquot. | |
Transport temperature: |
Refrigerated (cold packs). | |
Specimen stability: |
Room temperature: 24 hours. Refrigerated: 7 days. Frozen: 30 days. | |
Rejection criteria: |
Received room temperature. | |
TEST DETAILS |
||
CPT code(s): |
83520 x6 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Ganglioside GM-1 Antibodies (IgG, IgM), EIA; Ganglioside GD1a Antibody (IgG, IgM), EIA; Ganglioside Asialo-GM-1 Antibody (IgG, IgM), EIA | |
Methodology: |
Immunoassay |
|
Synonyms: |
Quest test code 90131. Gang AB Pnl6
|
|
Clinical significance: |
The presence of antibodies to the gangliosides GM1, Asialo-GM1, and GD1a has been associated with motor neuropathies. High titers of antibody to GM1 are most typical of multifocal motor neuropathy; however, antibodies to other gangliosides are often present. In most cases, anti-ganglioside antibodies are IgM class. IgG antibodies have been reported less often, generally associated with acute conditions. Many reports have found increased anti-asialo-GM1 antibody titers in patients with multifocal motor neuropathy, lower motor neuron disease, or motor neuropathy with or without multifocal block, Guillain-Barré Syndrome, and amyotrophic lateral sclerosis. There may be a relationship between titers of asialo-GM1 antibodies and clinical status in individual patients. In some lower motor neuron disorders, improvement in strength has occurred after therapeutic reduction in anti-asialo-GM1 antibody titers. | |